What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the IMvigor 130 trial indicates that atezolizumab significantly improves overall survival (18.6 months vs. 10.0 months for platinum-based chemotherapy) with a hazard ratio of 0.50 (95% CI 0.29 to 0.87, p=0.0125). This demonstrates a clear clinical advantage over standard care, although the evidence is based on a small subgroup of the trial population.
Does the economic case hold at the expected price? — Cost effectiveness
The incremental cost-effectiveness ratio (ICER) for atezolizumab is estimated at £32,235 per QALY gained, which is below the £50,000 threshold considered acceptable by NICE. This indicates that the treatment is clearly cost-effective under common thresholds.
Is there quality-of-life evidence payers weigh? — Quality of life
The committee acknowledged that urothelial cancer significantly impacts quality of life, and while the utility values used in the economic model were deemed appropriate, the evidence for HRQoL improvements specifically attributable to atezolizumab was not robustly established. However, the treatment is expected to provide some moderate improvements.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Atezolizumab is reported to be well tolerated with fewer adverse events compared to chemotherapy. While there are some serious adverse events associated with its use, they are manageable, leading to an overall acceptable safety profile.
Was the drug compared against what payers expect? — Comparator Selection
The clinical evidence primarily compares atezolizumab with carboplatin plus gemcitabine, but there was no direct comparison with best supportive care, which is a relevant comparator for patients ineligible for cisplatin. This lack of data limits the robustness of the comparative effectiveness assessment.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population in IMvigor 130 included a relevant subgroup of patients with untreated PD-L1-positive advanced urothelial cancer. However, there are concerns regarding the generalizability of the results due to differences in baseline characteristics and the small sample size.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Atezolizumab can be integrated into existing treatment pathways with minor adjustments, as it is an immunotherapy that offers a different side effect profile compared to traditional chemotherapy. This facilitates its adoption in clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of atezolizumab is manageable, especially considering the commercial arrangement that provides a discount. The treatment is expected to be resource-efficient relative to its benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is primarily derived from the IMvigor 130 phase 3 trial, which, despite some limitations regarding subgroup size and baseline differences, provides a strong foundation for decision-making. The data is supported by real-world evidence from the SACT dataset.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the treatment effects due to the small subgroup size and differences in baseline characteristics. The committee acknowledged these uncertainties but concluded that the treatment still meets the criteria for a life-extending treatment.
